Vivimed Labs reports FY26 standalone loss as CIRP begins
As filed · Vivimed Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
EarningsDeterioratingNotablemateriality 72 out of 100
What happened
FactVivimed Labs approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2026. The standalone financial statements report a loss for the year of 1,716.11, while the company said its net worth has been eroded and that CIRP was initiated on 15 April 2026.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
Evidence
How CapitSignal classified this
- Reasoning:
- The company is operating under CIRP, with Board powers suspended and management control vested in the IRP/RP. Its stated erosion of net worth and annual loss highlight the financial stress underlying the resolution process.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%